30 research outputs found
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone
International audienc
Correction: Bee Venom for the Treatment of Parkinson Disease - A Randomized Controlled Clinical Trial.
[This corrects the article DOI: 10.1371/journal.pone.0158235.]
Bee Venom for the Treatment of Parkinson Disease - A Randomized Controlled Clinical Trial.
TRIAL REGISTRATION
ClinicalTrials.gov NCT01341431
Baseline characteristics in the placebo / bee venom groups.
<p>Baseline characteristics in the placebo / bee venom groups.</p
Main results in the placebo / bee venom groups.
<p>Main results in the placebo / bee venom groups.</p
Bee Venom for the Treatment of Parkinson Disease – A Randomized Controlled Clinical Trial - Fig 2
<p>Evolution of the differences of UPDRS III (A), II (B) and total scores (C) with baseline over the 11 month study period in the placebo and bee venom groups.</p
Kinetics of bee venom specific antibodies.
<p>The sample at day -60 was taken at the pre-screening, the first bee venom injection was done at day 0 and the first sample after at day 30. Diamonds are for specific IgE (kU/L) and the squares for specific IgG4 (mg/L). (A)kinetics of specific IgE production for all patients; (B) kinetics for specific IgE and IgG4 for a single representative patient.</p
Comparison of [123I]-FP-CIT binding potential changes between V2 and V13 in the placebo / bee venom groups.
<p>Comparison of [123I]-FP-CIT binding potential changes between V2 and V13 in the placebo / bee venom groups.</p
Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriers
International audienceA (GGGGCC)n repeat expansion in C9orf72 gene is the major cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The relations between the repeats size and the age at disease onset (AO) or the clinical phenotype (FTD vs. ALS) were investigated in 125 FTD, ALS, and presymptomatic carriers. Positive correlations were found between repeats number and the AO (p < 10e-4) but our results suggested that the association was mainly driven by age at collection (p < 10e-4). A weaker association was observed with clinical presentation (p = 0.02), which became nonsignificant after adjustment for the age at collection in each group. Importantly, repeats number variably expanded or contracted over time in carriers with multiple blood samples, as well as through generations in parent-offspring pairs, conversely to what occurs in several expansion diseases with anticipation at the molecular level. Finally, this study establishes that measure of repeats number in lymphocytes is not a reliable biomarker predictive of the AO or disease outcome in C9orf72 long expansion carriers